Hml. Ball et al., Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring, BR J CANC, 85(8), 2001, pp. 1102-1105
Fine needle aspiration (FNA) biopsy is the least invasive method of samplin
g breast cancer in vivo and provides material for breast cancer diagnosis.
FNA has also been used to examine cellular markers to predict and monitor t
he effects of therapy. The aim of this study was to assess the accuracy of
using FNA material compared with resected cancer for Western blotting studi
es of the p53 pathway, a key to tumour response to radiotherapy and chemoth
erapy. Paired samples of breast cancer FNAs collected pre-operatively and p
ost-operatively were compared with tissue samples obtained at the time of s
urgical resection. Western blots were probed for p53 using the antibodies D
O12 and DO1, and for levels of downstream proteins p21/WAF1 and p27. The pr
otein extracted by FNA was sufficient for up to 5 Western blot studies. p53
expression and phosphorylation did not differ significantly pre- and post-
operatively, indicating that intra-operative manipulation does not affect p
53 expression or downstream activation in breast cancer. However, expressio
n of p53, p21 and p27 varied between individual patients suggesting a range
of p53 pathway activation in breast cancer. Immunohistochemistry confirmed
that the cancer cells accounted for the protein expression detected on Wes
tern blots. FNA yields adequate protein for Western blotting studies and co
uld be used as a method to monitor p53 activity in vivo before and during a
nti-cancer treatment possibly providing early evidence of tumour response t
o therapy. (C) 2001 Cancer Research Campaign.